Purpose: To predict the invasiveness of urothelial bladder carcinoma using a logistic regression model on preoperative peripheral blood samples. Patients and Methods: Hospital data of patients operated for urothelial carcinoma were reviewed retrospectively. Preoperative blood samples were collected before the first cystoscopic examination. Any kind of infection or inflammation was an exclusion criterion. Patients were grouped as having a non-muscle-invasive or muscle-invasive urothelial carcinoma. The mean age was 69 years and was determined as the cut-off value. According to receiver operating characteristic curves, threshold points were determined for lymphocytes, neutrophil count, neutrophil-to-lymphocyte ratio (NLR), thrombocytes and mean platelet volume. Demographic specialties, parameters obtained from blood samples, tumor size and multiplicity were evaluated and significant parameters were put into a logistic regression model. Results: The study group consisted of 80 non-muscle-invasive and 102 muscle-invasive patients. Age (≤69 vs. >69), female gender, NLR (2.57), mean platelet volume (7.9/fl) and platelet count (400,000/µl) were significant parameters and put in a model. Using odds ratios, the probability of tumor invasiveness was calculated by a formula. Conclusion: Age, female gender, NLR and platelet count were found to be the predictors of invasiveness of urothelial carcinoma.

Keywords:
Urothelial carcinoma, Neutrophil, Lymphocyte, Neutrophil-to-lymphocyte ratio, Platelets, Logistic regression model
1.
Ferlay J, Shin HR, Bray F, et al: Cancer Incidence and Mortality Worldwide: International Agency for Research on Cancer, 2010. Available from: http://globocan.iarc.fr.
2.
Jaeger N, Radeke HW, Adolphs HD, et al: Value of intravesical sonography in tumor classification of bladder carcinoma. Eur Urol 1986;12:76–84.
3.
Sakai I, Miyake H, Harada KI, et al: Analysis of factors predicting intravesical recurrence of non-muscle invasive transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int J Urol 2006;13:1389–1392.
4.
Prescott S, James K, Hargreave TB, et al: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636–1642.
5.
Taniguchi K, Koda S, Nishikido M, et al: Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for non-muscle invasive bladder cancer. Clin Exp Immunol 1999;115:131–135.
6.
Yamashita J, Ogawa M, Shirakusa T: Free form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J Leukoc Biol 1995;57:375–378.
7.
Ohno Y, Nakashima J, Ohori M, et al: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010;184:873–878.
8.
Levin J, Conley CL: Thrombocytosis associated with malignant disease. Arch Intern Med 1964;114:497–500.
9.
Sierko E, Wojtukiewicz MZ: Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004;30:95–108.
10.
Nascimento CM, Drager BJ, Zeegers MP, et al: Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 2007;25:285–295.
11.
Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
12.
Madeb R, Messing EM: Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004;22:86–92.
13.
Linn JF, Sesterhenn I, Mostofi FK, et al: The molecular characteristics of bladder cancer in young patients. J Urol 1998;159:1493–1496.
14.
Totterman TH, Loskog A, Essand M: The immunotherapy of prostate and bladder cancer. BJU Int 2005;96:728–735.
15.
Yamada H, Luo Y, Matsumoto T, et al: A novel expression of macrophage derived chemokine in human bladder cancer. J Urol 2005;173:990–995.
16.
McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215–219.
17.
Walsh SR, Cook EJ, Goulder F, et al: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181–184.
18.
Mantovani A, Allavena P, Sica A, et al: Cancer related inflammation. Nature 2008;454:436–444.
19.
O’Toole C, Perlman P, Unsgaard B, et al: Cellular immunity to human urinary bladder carcinoma. Correlation to clinical stage and radiotherapy. Int J Cancer 1972;10:77–91.
20.
Hirashima M, Higuchi S, Sakamoto K, et al: The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol 1998;124:329–334.
21.
Lasek WA, Plodziszewska M, Gorecki D, et al: Relationship between natural killer activity and eosinophil, neutrophil and lymphocyte level in human blood. Folia Haematol 1985;117:907–912.
22.
Kishi Y, Kopetz S, Chu YS, et al: Blood neutrophil-to lymphocyte ratio predicts survival in patients with colorectal liver metastasis treated with systemic chemotherapy. Ann Surg Oncol 2009;16:614–622.
23.
Gomez D, Farid S, Malik HZ, et al: Preoperative neutrophil-to lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008;32:1757–1762.
24.
Zahorec R: Ratio of neutrophil-to-lymphocyte counts. Rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5–14.
25.
Nieswandt B, Hafner M, Echtenacher B, et al: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295–1300.
26.
Kim YJ, Borsig L, Varki NM, et al: P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998;95:9325–9330.
27.
Suppiah R, Shaheen PE, Elson P, et al: Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006;107:1793–1800.
28.
Ikeda M, Furukawa H, Imamura H, et al: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287–291.
29.
Todenhöfer T, Renninger M, Schwentner C, et al: A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU Int DOI: 10.1111/j.1464-410X.2012.11231.x.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.